Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase.
Jian Wang, Li Zhu, Zhiyi Zhang...
https://pubmed.ncbi.nlm.nih.gov/38835029Actively Recruiting
All Genders
ID03097952
"Real-life" Cohort Study on Patients With Chronic Hepatitis B Virus Infection in Jiangsu
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2017-03-31
20000
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic hepatitis B virus (HBV) infection is a major global health issue that can lead to serious liver problems such as cirrhosis, liver cancer, and death. This observational study aims to gather detailed information from a broad group of Chinese patients with chronic HBV infection to better understand the factors that influence disease outcomes. The study involves creating a comprehensive database of clinical, epidemiological, biological, virological, immunologic, and treatment-related data from patients with chronic HBV infection. There are no drug interventions; instead, participants are monitored as part of this long-term cohort. Participants will be followed over many years, with researchers tracking outcomes like loss of hepatitis B antigens, development of cirrhosis, liver failure, liver cancer, and mortality. Regular assessments will collect relevant health information to help identify the factors linked to disease progression. The study is planned to continue until 2030, providing extensive long-term data on chronic HBV infection.
CONDITIONS
Brief Title
"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with chronic HBV infection (defined as HBsAg positive for at least 6 months)
You will not qualify if you...
- Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) and/or hepatitis D virus (HDV)
- History of liver transplantation
- History of hepatocellular carcinoma (HCC)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Long-term Monitoring
Duration - Up to 20 years
Participants with chronic HBV infection are observed over time to monitor disease progression and clinical outcomes.
Trial Site Locations
Total: 6 locations
1
The Third Hospital of Changzhou
Changzhou, Jiangsu, China, 213001
Actively Recruiting
2
Huai'an No.4 People's Hospital
Huai'an, Jiangsu, China, 223300
Actively Recruiting
3
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 210008
Actively Recruiting
4
Nanjing Jiangbei People's Hospital
Nanjing, Jiangsu, China, 210048
Actively Recruiting
5
Suqian People's Hospital
Suqian, Jiangsu, China, 223800
Actively Recruiting
6
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China, 215007
Actively Recruiting
Loading map...
Research Team
C
Chao Wu, M.D., Ph.D
R
Rui Huang, M.D., Ph.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study.
Renling Yao, Sufang Lu, Ruifei Xue...
https://pubmed.ncbi.nlm.nih.gov/37742745Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease.
Jian Wang, Jiacheng Liu, Yilin Liu...
https://pubmed.ncbi.nlm.nih.gov/36317959